Latest Breaking News On - Torrey pines mesa - Page 8 : comparemela.com
Reply
More than 84,000 San Diego County residents are living with Alzheimer s, while more than 200,000 residents care for someone with the disease. (Shutterstock / Tashatuvango)
SAN DIEGO, CA An alliance of local research institutions announced Wednesday the National Institute on Aging has awarded it $7.46 million in federal grants to advance research to combat Alzheimer s disease.
The funds are headed to Collaboration4Cure, an alliance of top research institutions brought together by San Diego County and Alzheimer s San Diego. C4C grew out of the work of The Alzheimer s Project, a regional effort to address a rise in local cases of dementia, the region s third-leading cause of death after cancer and heart disease.
California
United-states
San-diego
San-diego-county
White-house
District-of-columbia
Dianne-jacob
Shutterstock-tashatuvango
Eugenia-welch
Darlene-shiley
Sanford-burnham-prebys
Joe-biden
San Diego’s Locanabio raises $100 million for treatments aimed at degenerative diseases [The San Diego Union-Tribune]
Locanabio, a San Diego gene therapy company focused on treatments for severe neurodegenerative diseases such as Huntington’s and Lou Gehrig’s disease, has raised $100 million in a second round of venture capital funding.
The Torrey Pines Mesa company will use the money for further pre-clinical and clinical development of its proprietary RNA-targeting system to fight degenerative diseases including myotonic dystrophy type 1 and retinal disease, along with Huntington’s and genetic ALS.
Locanabio’s approach is to combine two methods for treating diseases gene therapy and RNA modification. The platform consists of several RNA-targeting systems that are combined with gene therapy delivery to modify dysfunctional RNA.
San-diego
California
United-states
Lou-gehrig
Jim-burns
Rajul-jain
Torrey-pines-mesa
Temasek
San-diego-union
Tribune-content-agency
Chief-executive-jim-burns
Acuta-capital-partners
Print
Locanabio, a San Diego gene therapy company focused on treatments for severe neurodegenerative diseases such as Huntington’s and Lou Gehrig’s disease, has raised $100 million in a second round of venture capital funding.
The Torrey Pines Mesa company will use the money for further pre-clinical and clinical development of its proprietary RNA-targeting system to fight degenerative diseases including myotonic dystrophy type 1 and retinal disease, along with Huntington’s and genetic ALS.
Locanabio’s approach is to combine two methods for treating diseases gene therapy and RNA modification
. The platform consists of several RNA-targeting systems that are combined with gene therapy delivery to modify dysfunctional RNA.
San-diego
California
United-states
Lou-gehrig
Jim-burns
Rajul-jain
Torrey-pines-mesa
Temasek
Chief-executive-jim-burns
Acuta-capital-partners
Lightstone-ventures
Google-ventures
vimarsana © 2020. All Rights Reserved.